




		<b>EMLc</b>	<b>ATC codes: J04BA01</b>
<b>Indication</b>	Multi-drug resistant Mycobacterium tuberculosis	<b>ICD11 code: ML32.00</b>	
<b>INN</b>	Clofazimine		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Additional notes</b>	Reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.		
<b>Formulations</b>	Oral > Solid: 100 mg ; 50 mg		
<b>EML status history</b>	First added in 2017 ( <a href="#">TRS 1006</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents.</a> 		
<b>Wikipedia</b>	<a href="#">Clofazimine</a> 		
<b>DrugBank</b>	<a href="#">Clofazimine</a> 		

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended an amendment to the dosage form terminology for clofazimine, replacing 'capsule' with 'solid oral dosage form'.

